New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-phase trial tests a new drug called IMA401, which helps the immune system attack cancer cells. It is for adults with advanced solid tumors (like lung or head and neck cancer) that have come back or stopped responding to treatment. The study checks safety, the right dos…
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC